Myelomonocytic Leukemia
📧 Sign up to get email alerts when something new happens for Myelomonocytic Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-09-18Clinical Trial Update: Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients [Phase 1]
Phase 1 trial evaluating Itacitinib with high-dose posttransplantation cyclophosphamide in older patients. The study is currently ACTIVE_NOT…
-
CLINICAL_TRIALS research · 2025-08-26Clinical Trial Update: Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia [Phase 1, Phase 2]
A phase 1/2 clinical trial is evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of Tuspetinib (HM43239) in patients…
-
CLINICAL_TRIALS research · 2025-08-26Clinical Trial Update: Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML [Phase 2]
Phase 2 clinical trial evaluating a metabolically optimized, non-cytotoxic, low-dose weekly decitabine/venetoclax regimen in myelodysplastic…
-
CLINICAL_TRIALS research · 2025-08-21Clinical Trial Update: Pacritinib in CMML [Phase 1, Phase 2]
Clinical trial update indicating Pacritinib is being studied for Chronic Myelomonocytic Leukemia in Phase 1/Phase 2 and is currently recruit…
-
CLINICAL_TRIALS research · 2025-08-15Clinical Trial Update: The Kinetics Profiling of Immune Reconstitution and Clinical Outcomes
Clinical trial update on the kinetics profiling of immune reconstitution and clinical outcomes in chronic myelomonocytic leukemia; the study…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-07-03Clinical Trial Update: Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations [Phase 2]
Phase 2 clinical trial evaluating eltrombopag as a treatment for low-risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia with…
-
CLINICAL_TRIALS research · 2025-06-27Clinical Trial Update: Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations [Phase 1]
Phase 1 study of oral LY3410738 in patients with IDH1/IDH2-mutant hematologic malignancies is currently active but not recruiting.
-
CLINICAL_TRIALS research · 2025-06-27Clinical Trial Update: Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning [Phase 2]
Phase 2 trial evaluating vedolizumab with post-transplant cyclophosphamide and tacrolimus to prevent graft-versus-host disease in patients u…
-
CLINICAL_TRIALS research · 2025-06-10Clinical Trial Update: Oral-ATO for TP53-mutated Myeloid Malignancies [Phase 2]
A Phase 2 clinical trial evaluating oral arsenic trioxide for TP53-mutated myeloid malignancies, including acute myeloid leukemia and myelod…
-
CLINICAL_TRIALS research · 2025-06-04Clinical Trial Update: ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis [Phase 2]
A Phase 2 trial (ABBA CORD) evaluating donor-derived cord blood T cells with abatacept for prophylaxis of acute graft-versus-host disease in…
-
CLINICAL_TRIALS research · 2025-05-30Clinical Trial Update: Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants [Phase 2]
Phase 2 clinical trial update describing the addition of itacitinib to cyclophosphamide and tacrolimus for preventing graft-versus-host dise…
-
CLINICAL_TRIALS research · 2025-05-28Clinical Trial Update: Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002) [Phase 1]
An early-phase clinical trial evaluating Tagraxofusp as post-transplant maintenance in patients with CD123-positive acute myeloid leukemia, …
-
CLINICAL_TRIALS research · 2025-05-18Clinical Trial Update: A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML [Phase 1, Phase 2]
Clinical trial update showing CFI-400945 with or without azacitidine is being studied in acute myeloid leukemia, myelodysplastic syndromes, …
-
CLINICAL_TRIALS research · 2025-04-17Clinical Trial Update: Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial [Phase 2]
Phase 2 trial evaluating fecal microbiota transplantation before allogeneic stem cell transplant; recruitment is ongoing across multiple hem…
-
CLINICAL_TRIALS research · 2025-04-15Clinical Trial Update: Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT) [Phase 1]
Phase 1 clinical trial assessing a preventive therapy to reduce graft-versus-host disease in participants with hematologic malignancies unde…
-
CLINICAL_TRIALS research · 2025-04-04Clinical Trial Update: Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant [EARLY_Phase 1]
An early-phase 1 clinical trial is evaluating hyperbaric oxygen therapy in combination with allogeneic peripheral blood stem cell transplant…
-
CLINICAL_TRIALS research · 2025-03-28Clinical Trial Update: Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients [Phase 2]
Phase 2 clinical trial evaluating selinexor in combination with azacitidine for high-risk myeloid neoplasms, currently not yet recruiting.
-
CLINICAL_TRIALS research · 2025-03-20Clinical Trial Update: A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia [Phase 3]
A Phase 3 trial comparing oral decitabine/cedazuridine with azacitidine in myelodysplastic syndromes, acute myeloid leukemia with low blast …
-
CLINICAL_TRIALS research · 2025-01-14Clinical Trial Update: Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies [Phase 1]
This Phase 1 trial from Epigenetix, Inc. is evaluating a dual BET and CBP/p300 inhibitor across targeted advanced solid tumors and hematolog…
-
CLINICAL_TRIALS research · 2024-12-20Clinical Trial Update: GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG [Phase 3]
Phase 3 randomized trial comparing post-transplant cyclophosphamide versus anti-thymocyte globulin for graft-versus-host disease prophylaxis…
-
CLINICAL_TRIALS research · 2024-08-27Clinical Trial Update: Myeloproliferative Neoplasms (MPNs) Patient Registry
An update on the Myeloproliferative Neoplasms (MPNs) Patient Registry sponsored by University Health Network in Toronto, currently recruitin…
-
CLINICAL_TRIALS research · 2024-07-22Clinical Trial Update: Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary Involvement
This clinical trial is testing an intensive conditioning regimen consisting of Thiotepa, Busulfan, Fludarabine, and Cytarabine followed by a…
-
CLINICAL_TRIALS research · 2024-05-08Clinical Trial Update: Pilot Study of CC 486 (Oral Azacitidine) Plus BSC as Maintenance After sc Azacitidine in Elderly HR-IPSS-R MDS Patients [Phase 2]
Pilot Phase 2 study evaluating CC-486 (oral azacitidine) plus best supportive care as maintenance after subcutaneous azacitidine in elderly …
-
CLINICAL_TRIALS research · 2024-05-03Clinical Trial Update: Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition [Phase 1]
A Phase 1 clinical trial at Fox Chase Cancer Center tests the combination of pacritinib and talazoparib in myeloproliferative neoplasms unre…
-
CLINICAL_TRIALS research · 2024-05-01Clinical Trial Update: Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML [Phase 1, Phase 2]
A Phase 1/2 clinical trial assessing adding venetoclax to FLAMSA/treosulfan conditioning for allogeneic stem cell transplantation in patient…